Maintenance Olaparib in Advanced Ovarian Cancer: SOLO-1 Long-Term Survival Update
Posted: Friday, October 23, 2020
Almost half of patients who received maintenance olaparib for newly diagnosed BRCA-mutated advanced ovarian cancer remained disease-free after 5 years, according to data from a long-term follow-up of the SOLO-1 trial presented during the European Society for Medical Oncology (ESMO) Virtual Congress 2020 (Abstract 811MO). Only 20% of patients who received a placebo were disease-free after 5 years.
“These results represent a significant step forward in the treatment of newly diagnosed advanced ovarian cancer and give us real hope for more long-term survivors,” stated Susana Banerjee, MBBS, PhD, of the Royal Marsden Hospital NHS Foundation Trust and Institute of Cancer Research, London, in a Royal Marsden press release.
In this phase III study, 391 patients were randomly assigned to receive olaparib (n = 260) or placebo (n = 131). Patients received maintenance olaparib at 300 mg twice daily or placebo for up to 2 years or until disease progression. The duration of treatment in each arm was 24.6 and 13.9 months, respectively.
After a median follow-up of 4.8 years in the olaparib arm and 5.0 years in the placebo arm, 48.3% of patients treated with olaparib had not experienced disease progression and were still living with stable disease compared with 20.5% of those taking placebo. The median progression-free survival was 56 versus 14 months, respectively. Among patients in complete response at baseline, the risk of disease recurrence or death was reduced by 63%. The safety profile of olaparib was consistent with previous reports.
“SOLO-1 has given us the evidence to show that as a first-line therapy, it can have substantial benefit for patients earlier in the cancer pathway,” concluded Dr. Banerjee.
Disclosure: For full disclosure of the study authors, visit oncologypro.esmo.org.
